Prices delayed by at least 15 minutes | Print


AETERNA ZENTARIS INC (AEZS)

Equity
Sell: 2.45 CAD|Buy: 2.78 CAD|Change: 0.01 (-0.37%)

Open 

2.68 CAD


Previous close 

2.67 CAD


Trade high 

2.68 CAD


Volume 

16


Year high 

4.48 CAD


Year low 

1.91 CAD


Dividend yield 

-


Market capitalisation 

12.92 mn CAD


P/E ratio 

-


ISIN 

CA0079755017


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 24/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
AETERNA ZENTARIS INC 0.00
More...

Company profile

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success &safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland which generates key revenue, Ireland, Denmark, and others.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.